Time: 2024-07-08
CSL Limited , listed on the ASX under the ticker ASX : CSL , has recently seen a surge in its Share price , outperforming the broader S&P / ASX 200 Health Care Index . In a note released by Citi , the biotech giant 's shares were upgraded to a ' buy ' rating , with a price target of 35 per share . This represents a potential 12 % upside from the current trading price of 98.02.
In the first half of fiscal year 2024 , CSL reported a 17 % year - over - year growth in profits , reaching .9 billion , with earnings per share standing at .18 . The company 's management is optimistic about achieving a bottom - line figure of billion for the full year . Analysts at Baker Young also forecast a 21 % annual growth in profits for CSL over the next three years.
Several other brokerage firms have expressed positive sentiments towards CSL Limited . Macquarie , for instance , rates the company 's shares as a buy with a price target of 30 . The firm emphasizes the strength of CSL 's Behring division and anticipates a potential valuation of 00 per share by 2027 . This sentiment is echoed by Sam Byrnes from ECP Asset Management , who also predicts a 00 share price by 2027.
Morgans , on the other hand , has a more conservative price target of 15 for CSL shares but still sees significant earnings growth potential . Additionally , Wilsons Advisory has highlighted that CSL 's earnings trajectory is stronger than the broader market , potentially making its current valuation attractive.
With experts predicting further growth for CSL shares , investors are advised to carefully assess their financial situation and risk tolerance before considering any investment decisions . As the company trades at a forward price - to - earnings ratio of around 38 times , it is essential to conduct thorough research and evaluation before making any investment choices.
Business
